( n the U.S. Remember that this applies t...)2005 was a tough year for U.S. biotech financing

n the U.S. Remember that this applies to a little more than the 300 publicly-traded biotech companies in the U.S.

VC financing of $3.5 billion in 2005 was down 7 percent. This result is bad news for the 1200+ privately held biotech companies in the U.S. that depend mostly on VC financing. Assuming the number of 1200 companies, the average raise-up per company was less than $3 million in ......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 01/30/06


Page: 1 2 3 4 5
Related biology technology :

1. The tough choices facing health care
2. Venture-backed companies drive job creation, even in tough times
3. Vertical partnering: Street smarts for a tough marketplace
4. The state of global biotech: An Ernst & Young perspective
5. Olympics of biotechnology has international flavor
6. Getting noticed in Genetown: Wisconsin biotech on display
7. Madison biotech NimbleGen files for IPO; one of states best-funded firms
8. Wisconsin biotech firm receives $107K NIH grant
9. Manufacturing partnership will move into biotech and biomedical spaces
10. Wisconsin wont get Georgia biotech without a fight
11. The 10 biggest events shaping biotech in 2006